Pharma & Mergers

Mergers

Pharma and Mergers: An overview of EU and national case law
DLA Piper
,
Bona Law (New York)
1. Merger control in perspective e-Competitions, the private equivalent of the International Competition Network ("INC"), has reported close to 100 pharmaceutical mergers from all over the world since its inception in 2004 . They are included in this Special Issue. Like no other tool, (...)

The EU Commission clears a merger, subject to remedies, in the pharmaceutical sector (Meda / Mylan)
European Commission - DG COMP (Brussels)
Mergers: Commission clears acquisition of Meda by Mylan subject to conditions* The European Commission has approved under the EU Merger Regulation the proposed acquisition of Meda AB of Sweden by Mylan N.V. of the Netherlands, subject to conditions. Both companies operate in the pharmaceutical (...)

The Chinese MOFCOM fines several undertakings for breaches of merger notification rules (FJEI / FPID / Nanjing Puzhen / Bombardier Sweden / BestTv / Microsoft)
AnJie Law (Beijing)
,
AnJie Law (Beijing)
Warning from MOFCOM: Second Wave of Penalties Imposed for Breaches of Concentration Notification Rules* On September 29th 2015, the Ministry of Commerce of the P.R.C (“MOFCOM”) published four administrative decisions on penalties for illegal activities involved in the concentration of (...)

The UK Competition Authority orders licensing remedy to meet concerns over horizontal unilateral effects resulting from a merger in the personal lubricants market (Reckitt Benckiser / Johnson & Johnson)
Herbert Smith Freehills (Brussels)
Introduction and background On 4 November 2015, the UK Competition and Markets Authority ("CMA") accepted final undertakings from Reckitt Benckiser Group plc ("RB") and Johnson & Johnson ("J&J") in relation to RB’s proposed acquisition from J&J of the K-Y brand of personal lubricant (...)

The Polish Minister of the State Treasury gains the power to control mergers and acquisitions in strategic sectors
Wiercinski Kwiecinski Baehr (Poznan)
The Minister of the State Treasury will control mergers and acquisitions in strategic sectors of Polish economy* On 30 September 2015, the Act on Control of Certain Investments (the “Act”) enters into force. The Act aims to create mechanisms to protect against hostile takeovers of companies (...)

The FTC challenges a merger in regional markets for sterilization of products using radiation based on future competition concerns (Steris / Synergy Health)
Doyle, Barlow & Mazard
FTC Challenges Deal Based on Future Competition Concerns* On May 29, 2015, the Federal Trade Commission (“FTC”) issued an administrative complaint alleging that Steris Corporation’s (“Steris”) proposed $1.9 billion acquisition of Synergy Health plc (“Synergy”) would violate the antitrust laws by (...)

The EU Commission conditionally clears a merger following an in-depth investigation (Zimmer / Biomet)
European Commission - DG COMP (Brussels)
Introduction On 30 March 2015, the European Commission conditionally cleared Zimmer’s acquisition of Biomet, following an in-depth investigation. Zimmer and Biomet are two of the five leading competitors in the medical implants industry. The transaction was initially notified on 3 June 2014, (...)

The EU Commission conditionally approves deals in the pharmaceutical sector extending its analysis of pipeline pharmaceutical products (GSK / Novartis)
European Commission - DG COMP (Brussels)
,
European Commission - DG COMP (Brussels)
,
European Commission - DG COMP (Brussels)
"Protecting the drugs of tomorrow : competition and innovation in healthcare"* In a nutshell : In Novartis/GSK Oncology, the Commission extended its analysis of pipeline pharmaceutical products beyond those that are in advanced stages of development (phase III), to fully assess the (...)

The Competition Commission of India directs for the first time a divestiture of assets in a merger case (Sun-Ranbaxy)
Economic Laws Practice
,
Economic Laws Practice
Introduction The Competition Commission of India (“CCI”) for the first time has directed divestitures of assets, before granting its final approval, in a combination relating to merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharmaceutical Industries Limited (“Sun Pharma”) (referred (...)

The UK Competition and Markets Authority refuses to apply the failing firm defence to clear a merger in phase II (Alliance / IBA)
St John’s Chambers
United Kingdom Merger Control: Recent Developments in the Failing Firm Defence* On 15 August 2014, the Competition and Markets Authority (“CMA”) approved Alliance Medical Group’s completed acquisition of IBA Molecular’s radioactive medical tracer business. Although IBA’s business was loss-making, (...)

The UK’s Business secretary proposes new safeguards to counteract the threat of foreign takeovers to the national interest (Pfizer/AstraZeneca)
UEA law school - Centre for Competition Policy
Pfizer/AstraZeneca and the Public Interest: Do Vince Cable’s Foreign Takeover Proposals Prescribe the Right Medication?* When US pharmaceutical giant Pfizer sought to acquire its UK-listed counterpart AstraZeneca earlier this year, discussion centred around the supposed adverse impact that the (...)

The New Zealand Commerce Commission publishes statement of preliminary issues following merger notification on the market for pharmacy wholesaling
New Zealand Commerce Commission
Press releases published on New Zealand Commerce Commission Statement of preliminary issues published for CDC Pharmaceutical and Pharmacy Wholesalers merger* CDC Pharmaceuticals and Pharmacy Wholesalers (Central) seek clearance to merge The Commerce Commission has received a joint (...)

The US FTC states that in order to address the competition concerns raised by the proposed acquisition of pharma laboratories, a settlement agreement to sell or relinquish rights to generics pharmaceuticals has been tentatively accepted (Actavis)
Stanford University - Stanford Law School
U.S. FTC makes Actavis’ acquisition of Forest subject to conditions* On 30 June 2014, the U.S. Federal Trade Commission (“FTC”) stated that, in order to address the competition concerns raised by Actavis’s proposed acquisition of Forest Laboratories, it has tentatively accepted the proposed (...)

The Australian Competition and Consumer Commission conditionally approves the proposed acquisition in life science sector (Life Technologies / Thermo Fisher Scientific)
Australian Competition and Consumer Commission
ACCC conditionally approves the proposed acquisition of Life Technologies by Thermo Fisher* The Australian Competition and Consumer Commission has announced that it will not oppose the proposed acquisition of Life Technologies Corporation by Thermo Fisher Scientific Inc after competition (...)

The Danish Competition Council conditionally approves acquisition on the market for veterinary drugs (Vilomix / Hatting-KS)
Danish Competition and Consumer Authority (Copenhagen)
Danish Competition Council approves Vilomix Holding A/S’ acquisition of A/S Hatting-KS conditional on commitments* On October 23th 2013 the Danish Competition Council (“DCC”) approved Vilomix Holding A/S’ (Vilomix) acquisition of A/S Hatting-KS (Hatting). The DCC decision is conditional on a (...)

The Irish Competition Authority clears a merger between a pre-wholesaler and a wholesaler of pharmaceutical, healthcare and veterinary products (Uniphar & CMR)
Irish Competition Authority
Competition Authority clears proposed acquisition of CMR by Uniphar* The Competition Authority has cleared the proposed transaction whereby Uniphar plc would acquire Cahill May Roberts Limited. The transaction was notified by the parties under the Competition Act 2002 on 12 December 2012 and (...)

The Portuguese Competition Authority imposes record fine for gun-jumping (Farminveste)
Van Bael & Bellis (Brussels)
,
Van Bael & Bellis (Brussels)
At the end of December 2012, the Portuguese Competition Authority fined the Portuguese National Pharmacy Association and two subsidiaries of Portuguese company Farminveste € 150,000 for implementing their acquisition of pharmaceutical company ParaRede-Glintt without obtaining prior merger (...)

The US FTC proposes revisions to the premerger notification rules for pharmaceutical patent licensing transactions
Crowell & Moring (Washington)
The FTC’s Proposed Revisions to the Premerger Notification Rules for Pharmaceutical Patent Licensing Transactions* Recent developments On August 13, 2012, the Federal Trade Commission (“FTC”) released proposed amendments to the Hart-Scott-Rodino (“HSR”) premerger notification rules relating to the (...)

US antitrust agencies propose new Hart-Scott-Rodino merger control rules to require enhanced reporting of pharma, biological and diagnostic licenses
Thompson Hine (New York)
New FTC/DOJ position will require heightened regulatory reporting of pharma, biological and diagnostic licenses* The Federal Trade Commission and Department of Justice recently announced revisions to the Hart-Scott-Rodino (HSR) Act’s premerger notification rules to require enhanced reporting of (...)

The US Court of Appeals for the 8th Circuit upholds a lower court’s finding that the FTC failed to show the relevant market in a case concerning the acquisition of two drugs treating a similar heart defect (Lundbeck)
Scharf Banks Marmor
What Is a Relevant Market Anyhow?* The Eight Circuit, in FTC v. Lundbeck, Inc., No. 10-3458/3459 (Aug. 19, 2011), upheld the district court’s finding that the FTC failed to show a relevant market, and thus was unable to challenge the acquisition of the drug NeoProfen. It already owned a drug (...)

The European Commission waives commitment imposed on a merger in the DNA probes sector (Hoffmann-La Roche/Boehringer Mannheim)
Van Bael & Bellis (Brussels)
In a recently published decision of 3 May 2011, the European Commission waived certain commitments imposed as a condition of its approval of the acquisition of Boehringer Mannheim by Hoffman-La Roche in February 1998. In the 1998 decision, the Commission found that Hoffman-La Roche’s dominant (...)

The US FTC and the State of Minnesota appeal the district court’s decision on relevant market issue in a pharmaceutical merger case (Lundbeck)
Cleveland-Marshall School of Law
Some Reflections on the Lundbeck Appeal: Will Pharmaceuticals Get a Blanket Antitrust Immunity? And Is Quality Competition No Longer Protected by Antitrust?* A decision to watch for this year is the Eighth Circuit’s pending consideration of FTC v. Lundbeck, Inc., 2010-2 Trade Cases ¶77,160; 2010 (...)

The UK Office of Fair Trading holds that merger between two laboratories does not require referral to the Competition Commission under the Enterprise Act 2002 (Reckitt Benckiser)
University of Southampton
I. Introduction The Office of Fair Trading (OFT) has decided the merger between Reckitt Benckiser Inc. (Reckitt) and Combe Incorporated (Combe) will not substantially lessen competition in the market for the supply of certain pharmaceutical products. The merger does not have to be referred to (...)

The Netherlands Competition Authority clears pharmacies merger, subject to divestiture of four pharmacies (Brocacef/Lloyds Nederland)
Liberty Global (Amsterdam)
The merger The merger involved the acquisition of Lloyds Nederland BV («Lloyds») by Brocacef Holding NV («Brocacef»). Lloyds operated 63 pharmacies in the Netherlands at the time of the decision by the Netherlands competition authority («NMa») and is a subsidiary of the German group Celesio AG. (...)

A US district court rules against the FTC holding that it has failed to prove the relevant market in pharmaceutical merger case (Lundbeck)
Wolters Kluwer (Riverwoods)
FTC Loses Suit against Drug Maker over 2006 Acquisition* The Federal Trade Commission recently suffered a significant setback in its merger enforcement efforts when the federal district court in Minneapolis rejected an action brought by the agency along with the State of Minnesota against (...)

The US DoJ and FTC issue new merger guidelines suggesting increased focus on deals in high tech and pharmaceutical sectors
Gibson Dunn (New York)
New U.S. Merger Guidelines Suggest Increased Focus on Deals in High Tech and Pharmaceutical Sectors* In August 2010, the U.S. antitrust agencies released the final version of their revised Horizontal Merger Guidelines, which they use to analyze the competitive implications of mergers between (...)

The Chinese MOFCOM imposes conditions on merger in pharmaceutical industry (Novartis / Alcon)
Jones Day (Beijing)
,
Gibson Dunn (Hong Kong)
,
Jones Day (Beijing)
After a four-month review, on 13 August 2010, China’s Ministry of Commerce (“MOFCOM”) authorized Novartis‘ acquisition of Alcon subject to conditions. Taking different approaches than one would see in the U.S. or European Union, MOFCOM’s decision is notable for the demanding view it takes of (...)

The US FTC imposes remedies before clearing a merger affecting multiple markets for animal health and pharmaceutical products (Pfizer / Wyeth)
Akin Gump Strauss Hauer & Feld (Dallas)
The FTC entered into a consent agreement with Pfizer Inc. and Wyeth, requiring divestiture of one entity’s U.S. operations in over 20 markets for various animal health and pharmaceutical products. The consent order, established on January 25, 2010, sets forth the divestiture of Wyeth’s U.S. (...)

The Chinese MOFCOM conditionally clears major overseas transaction in the pharmaceuticals industry (Pfizer / Wyeth)
WilmerHale (Beijing)
,
WilmerHale (Beijing)
China’s Ministry of Commerce (MOFCOM) has just cleared two major overseas transactions, Pfizer’s acquisition of Wyeth in the pharmaceuticals industry and General Motors’ reacquisition of elements of auto parts manufacturer Delphi on September 28 and 29, respectively. Both clearances were subject (...)

The US FTC files a complaint to stop a proposed merger between two leading producers of plasma-derivative protein therapies (CSL, Talecris)
Jones Day (Washington)
Just two weeks after the FTC filed a complaint seeking an injunction to stop the proposed $3.1 billion acquisition by Australia-based CSL Limited of Talecris Biotherapeutics Holding Corporation, the parties have withdrawn their plans for a merger. The announcement, made on June 8, 2009, came (...)

The Macedonian Administrative Court confirms a merger prohibition decision in the market for retail distribution of pharmaceutical products (Zegin)
University of Technology (Tallinn)
On 1 June 2006 Zegin, leading distributor of the pharmaceuticals on the territory of Skopje municipality agreed with two other retail distributors of medicines - Alkaloid and Pharma Corp. to acquire joint control over City Pharmacy in Skopje , which owned a network of pharmacies in the (...)

The European Commission gives conditional clearance to an acquisition in the production of generic medicines (Teva/Barr Pharmaceuticals)
,
European Commission - DG COMP (Brussels)
"Mergers: main developments between 1 September and 31 December 2008"* On 19 December the Commission gave conditional approval to the proposed acquisition of Barr Pharmaceuticals of the US by Teva Pharmaceutical Industries of Israel. Both companies produce generic medicines. To remedy the (...)

The US FTC places a price cap on intra-company prices as a condition precedent to clearing a merger in the market for iron sucrose administrated intravenously (Fresenius / Daiichi)
Weil, Gotshal & Manges (Washington)
,
US Federal Trade Commission (FTC) (Washington)
On September 15, 2008, the FTC announced that it challenged a manufacturing, distribution, and supply agreement between Fresenius Medical Care Ag & Co. KGaA (Fresenius) and Daiichi Sankyo Company, Ltd. (“Daiichi”) based on allegations that the proposed transaction would violate U.S. (...)

The Estonian Competition Authority issues its first merger prohibition taking into account both previous acquisitions and potential future acquisitions in the pharmacy services sector (Terve Pere Apteek/Saku Apteek)
Jesse & Kalaus Attorneys
On 8 May 2008, the Director General of the Estonian Competition Authority (hereinafter the “ECA”) adopted a decision on the prohibition of the proposed acquisition of control over OÜ Saku Apteek (hereinafter “Saku Apteek”) by Terve Pere Apteek OÜ (hereinafter “TPA”). Since this is the first decision (...)

The European Commission conditionally clears a merger in the human and animal healthcare sector (Schering-Plough / Organon BioSciences)
,
European Commission - DG COMP (Brussels)
"Mergers: Main developments between 1 September and 31 December 2007"* On 11 October the Commission cleared the proposed acquisition of Organon BS of the Netherlands, a subsidiary of Akzo Nobel active worldwide in human and animal health, by the global pharmaceutical company Schering-Plough (...)

The European Commission conditionally clears a merger in the healthcare nutrition products sector (Nestle/Novartis)
,
European Commission - DG COMP (Brussels)
"Merger control: Main developments between 1 May and 31 August 2007"* In June the Commission approved the proposed acquisition of Novartis‘ Medical Nutrition business by Nestle. The approval was granted subject to the fulfilment of certain conditions. Nestle is active in the production, (...)

The US FTC seeks divestiture of rights and assets to five different medications before approving a merger, which would affect the markets for generic injectable pharmaceuticals (Hospira / Mayne)
Akin Gump Strauss Hauer & Feld (Dallas)
The FTC entered into a consent decree with Hospira Inc. and Mayne Pharma Ltd. on May 21, 2007 imposing divestitures on the firms prior to clearing their merger. The consent decree required Mayne to divest its current business in one type of generic pharmaceuticals, as well as the assets (...)

The Brussels Court of Appeal gives its opinion on the relationship between merger control and the Belgian equivalents of Art. 101 and 102 TFEU in what may be its last preliminary ruling (Rocco)
Altius (Brussels)
,
Altius (Brussels)
On 15 December 2006, the Brussels Court of Appeal ruled on the relationship between the merger control rules and the general rules on restrictive practices. The court’s judgment followed a request for a preliminary ruling to the Court from the Commercial Court of Namur. Background The (...)

The UK Office of Fair Trading clears a merger in the retail pharmacy services sector, subject to the divestment of four retail pharmacies (Admenta Lloyds/IPCC)
Eli Lilly and Company (London)
The operation Lloyds is owned by Admenta Holdings Limited, a subsidiary of the German company Celesio AG, which also owns the pharmaceutical wholesaler AAH. Independent Pharmacy Care Centres plc (IPCC) comprises 34 retail pharmacies and one drug store (the latter does not have an NHS (...)

The Spanish Competition Authority conditionally clears in phase II a merger in the wholesale distribution to pharmacy stores sector (Cofares/Hefame)
RBB Economics
The operation The operation involved the merger of Cofares and Hefame to create a new wholesale distributor of pharmacy products. Both Cofares and Hefame specialised in the wholesale distribution of pharmacy and parapharmacy products. They also provided other complementary services to (...)

The European Commission approves, subject to divestiture, an acquisition in the insurance sector (Gerling/Talanx)
,
European Commission - DG COMP (Brussels)
"Mergers — Main developments between 1 January and 30 April 2006"* On 5 April the proposed acquisition of the German insurance group Gerling by the insurer Talanx was approved. Talanx Aktiengesellschaft (‘Talanx‘) is a German holding company. Its subsidiaries offer life and non-life insurances to (...)

The UK Office of Fair Trading clears a merger in the market for the supply of retail pharmacy services, subject to the divestment of a large number of stores (Boots/Alliance Unichem)
Added Value Capital Partners (AVCP)
The operation Boots operates 1,423 health and beauty stores in the UK and operates pharmacies in 1,350 of these stores. It intended to acquire Alliance UniChem, an international pharmaceutical distribution company, which operates 958 pharmacies in the UK. The market(s) The OFT considered the (...)

The European Commission conditionally clears a merger leading to the creation of the largest European producer of generic medicines (Hexal/Eon Labs)
,
European Commission - DG COMP (Brussels)
"Mergers — Main developments between 1 May and 31 August 2005"* The Commission authorised the acquisition of Hexal, a German producer of generic medicines, and its US sister company Eon Labs by Novartis, in a deal which creates the largest European producer of generic medicines. The clearance (...)

The European Commission authorises an acquisition in the OTC industry creating the largest European OTC consumer health company (Roche / Bayer)
,
European Commission - DG COMP (Brussels)
"Merger control: Main developments between 1 September and 31 December 2004"* In November the Commission decided to authorise the acquisition of the worldwide Roche OTC business by Bayer in a deal which creates the largest European OTC consumer health company. The operation raised serious (...)

The Polish Competition Authority clears a merger in the pharmaceuticals sector, subject to a divestment remedy (Sanofi Synthelabo/Aventis)
Clifford Chance (Warsaw)
The operation The acquisition of Aventis by Sanofi-Synthelabo was performed by a public bid. The President of the OCCP, on 18 May 2004, cleared the merger, which led to the establishment of one of the largest pharmaceutical groups in the world (pages 3-5). The market(s) The President of the (...)

The European Commission conditionally clears a merger in the medical devices market (GE Medical Systems / Instrumentarium)
,
European Commission - DG COMP (Brussels)
"Merger Control: Main developments between 1st September 2003 and 31st December 2003"* In September the Commission approved, subject to conditions, the acquisition by GE Medical Systems of the Finnish firm Instrumentarium. The proposed acquisition was notified to the Commission on 28 February (...)

The Czech Competition Office clears a merger in the chemical sector subject to termination of an exclusive cooperation and business divestiture (DSM/Roche)
Clifford Chance
The operation On the basis of the share and property purchase agreement concluded between DSM N.V. ("DSM") and Roche Holding AG, Roche Finanz AG, Roche Vitamins Inc., Roche Farma SA, Roche Pharmaholding B.V., Roche Deutschland Holding GmbH and Hoffmann - La Roche France SAS, DSM acquired (...)

The European Commission clears the acquisition of the vitamins and fine chemicals division of a Swiss pharmaceutical company by a Dutch company after a detailed investigation (Roche/DSM)
European Commission - DG COMP (Brussels)
,
,
European Commission - DG COMP (Brussels)
"Merger control: main developments between 1st May and 31st August 2003"* On 23 July 2003, the European Commission cleared the proposed acquisition of the Vitamins and Fine Chemicals division of Swiss company Roche by Dutch-based company DSM after a detailed investigation. The Commission had (...)

The Czech Competition Office clears in a landmark decision in phase II a merger in the pharmaceutical sector subject to several structural and behavioural remedies, including transfer and divestment of trademarks and termination of a license agreement (Zentiva/S. L. Pharma)
Clifford Chance
The operation On the basis of share transfer agreement concluded on 20 January 2003, ZENTIVA B.V. ("Zentiva") acquired 100 % of shares in S.L. PHARMA HOLDING GESELLSCHAFT M.B.H. ("SLP") and therefore gained a sole control over the company. Zentiva operates in Czech Republic mainly through (...)

The Hungarian Competition Authority clears a merger in the sector of pharmacies with a posteriori condition including limited termination of control (UTA Pharma Beteiligungs/Pharma Concept)
lakatos, koves and partners
The operation Both UTA Pharma and Pharma Concept are trust and investment companies targeting to get indirect limited partnership in pharmacies and to finance them. The pharmacies in Hungary are established in the form of partnership with limited liability. The newly created merger would (...)

The EU Commission conditionally clears the merger of the medical ventilators, anaesthesia delivery systems and patient monitoring businesses of two German companies (Siemens / Drägerwerk)
European Commission - DG ECFIN
,
European Commission - DG COMP (Brussels)
,
European Commission - DG GROW
"Merger Control: Main developments between 1st January 2003 and 30th April 2003"* On 30 April 2003, the Commission approved, subject to conditions, the merger of the medical ventilators, anaesthesia delivery systems and patient monitoring businesses of Siemens AG and Drägerwerk AG, two German (...)

The Slovak Antimonopoly Office approves a merger in the sector of pharmacy with remedies including the divestiture of a business unit designated for a production of specific medicaments (Pfizer/Pharmacia)
Čechová & Partners
The operation By a decision dated 23 04 2003, the Antimonopoly Office of the Slovak Republic approved the acquisition of exclusive control of the undertaking Pfizer over the undertaking Pharmacia by a merger between the 100% subsidiary of Pfizer - company Pilsner Acquisition Sub Corp. and (...)

The European Commission conditionally clears a merger in the pharmaceutical sector creating the largest pharmaceutical company in the world in terms of sales and R&D spending (Pfizer/Pharmacia)
European Commission - DG ECFIN
,
European Commission - DG COMP (Brussels)
,
European Commission - DG GROW
"Merger Control: Main developments between 1st January 2003 and 30th April 2003"* The European Commission authorised, subject to conditions, the acquisition of Pharmacia Corporation (Pharmacia) by Pfizer Inc. (Pfizer) in a deal creating the largest pharmaceutical company in the world in terms (...)

The US FTC imposes divestiture of assets for one product and licensing of patents for two other products prior to approving a merger in the pharmaceuticals industry (Amgen / Immunex)
Akin Gump Strauss Hauer & Feld (Dallas)
Amgen Inc. and Immunex Corporation entered into a consent decree with the FTC on September 3, 2002 in order to proceed with the merger of the two pharmaceutical giants. To obtain clearance from the FTC, Amgen and Immunex agreed to divest Immunex’s business concerning the production of one (...)

The Hungarian Competition Office approves an acquisition in the pharmacy market with remedies including non-discrimination obligations and reporting commitments (Hungaropharma / Richter Gedeon)
lakatos, koves and partners
The operation The HCO authorized the acquisition of Hungaropharma by the consortium of Richter, Egis, Béres and Magyar Gyógyszer. Hungaropharma is owned by the Hungarian State. A sale and purchase agreement ("Agreement") was concluded by and between APV Rt and the Consortium. According to the (...)

The Hungarian Competition Office clears a merger in the pharmacies wholesale market sector with remedies including non-discrimination and reporting obligations (Hungaropharma)
lakatos, koves and partners
The operation The HCO authorized the acquisition of Hungaropharma by the consortium of Richter, Egis, Béres and Magyar Gyógyszer. Hungaropharma is owned by the Hungarian State. A sale and purchase agreement ("Agreement") was concluded by and between APV Rt and the Consortium. According to the (...)

The European Commission clears an acquisition in the markets for crop protection, professional pest control and animal health products subject to substantial divestitures (Bayer/Aventis/Crop Science)
European Commission - DG ECFIN
,
European Commission - DG COMP (Brussels)
,
Financial Conduct Authority (FCA)
"Merger Control: Main developments between 1st January 2002 and 30th April 2002"* The Commission decided to clear Bayer‘s acquisition of Aventis Crop Science (ACS), subject to substantial divestitures. As initially notified, the operation would have led to the creation or strengthening of (...)

The German Competition Authority prohibits the concentration plans that would have led to firms involved gaining dominant positions on certain markets in the wholesale pharmaceutical sector (Sanacorp / Andreae-Noris Zahn)
German Competition Authority (Bonn)
Bundeskartellamt prohibits Sanacorp/Andreae-Noris Zahn concentration* The Bundeskartellamt has prohibited the concentration plans of Sanacorp e.G. Pharmazeutische Grosshandlung, Planegg, (turnover in Germany approximately DM 3.89 billion) to acquire a majority holding in Andreae-Noris Zahn AG, (...)

The Turkish Competition Authority clears a merger in the pharmaceuticals sector subject to limitation of the non-compete clause (Abbott-BASF)
Esin
The operation Abbott is a USA based public company which is active in the field of discovery, improvement, manufacture and marketing of certain pharmaceutical products. Abbott holds 99.9% of its Turkish subsidiary which is also active in the pharmaceutical sector. BASF is a German public (...)

The European Commission clears an acquisition in the crop production industry (Astra Zeneca/Novartis)
Service européen pour l’action extérieure (EEAS)
,
Financial Conduct Authority (FCA)
,
European Commission - DG COMP (Brussels)
"Merger Control: main developments between 1st May 2000 and 31st August 2000"* In this operation, which will lead to the world.s leading crop protection business, Astra-Zeneca, itself created through the merger between Astra AB and Zeneca Group PLC in spring 1999, and Novartis, resulting from (...)

The EU Commission approves the creation of a joint venture in the pharmaceutical sector between a French company and a US company (Sanofi / Bristol-Myers Squibb)
European Commission - DG COMP (Brussels)
"Mergers : other developments"* The Commission approved the creation of a joint venture in the pharmaceutical sector between the French company Sanofi and the US company Bristol-Myers Squibb. The purpose of the cooperation is the development, manufacture and commercialisation of two new (...)

The European Commission clears, subject to divestiture, a merger in the pharmaceutical industry (Hoffmann-La Roche/Boehringer Mannheim)
European Commission - DG TRADE
,
"Mergers Recent important decisions" In September 1997, the Swiss pharmaceutical company Hoffmann-La Roche proposed to acquire Corage Ltd., ultimate parent company of the Boehringer Mannheim Group (BM). After a preliminary appreciation of the case the Commission concluded that in clinical (...)

The European Commission approves, subject to remedies, a merger in the health care, animal feed, crop protection and seeds sectors (Ciba-Geigy / Sandoz)
European Commission - DG GROW
"Mergers : Summary of the most important recent developments"* On 17th July, after four months of extensive investigations, the Commission approved the proposed merger between Ciba-Geigy and Sandoz into Novartis. The decision was granted under the condition that the parties comply with an (...)

The European Commission refers a proposed concentration in the wholesale and retail of pharmaceutical products to the competent UK authorities (GEHE/Lloyds)
"Mergers : Summary of the most important recent developments"* On 22nd March the Commission decided that the public bid by GEHE for Lloyds the Chemists should be referred to the competent United Kingdom authorities for further investigation. Through its AAH subsidiary, GEHE is currently the (...)

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues